Jiang, 148 patient metformin prophylaxis PSM study: 46% lower mortality [p=0.4] and 80% lower progression [p=0.02] https://c19p.org/jiang2
copied to clipboard
Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study
et al., Diabetes Research and Clinical Practice, doi:10.1016/j.diabres.2020.108619
Retrospective 328 COVID-19 patients with type 2 diabetes in China, showing significantly lower risk of ARDS with existing metformin use.
|
risk of death, 46.0% lower, HR 0.54, p = 0.40, treatment 3 of 74 (4.1%), control 10 of 74 (13.5%), adjusted per study, mixed effect Cox, propensity score matching.
|
|
risk of ARDS, 80.2% lower, RR 0.20, p = 0.02, treatment 8 of 74 (10.8%), control 17 of 74 (23.0%), NNT 8.2, adjusted per study, odds ratio converted to relative risk, mixed effect Cox, propensity score matching.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Jiang et al., 3/31/2021, retrospective, China, Asia, peer-reviewed, 12 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.